Posted by Michael Wonder on 30 Jan 2016
Merck receives FDA approval of Zepatier (elbasvir and grazoprevir) for the treatment of chronic hepatitis C virus genotype 1 or 4 infection in adults following priority review
28 January 2016 - Zepatier is a once-daily, fixed-dose combination tablet containing the NS5A inhibitor elbasvir (50 mg) and the NS3/4A protease inhibitor grazoprevir (100 mg).
For more details, go to: http://www.mercknewsroom.com/news-release/prescription-medicine-news/merck-receives-fda-approval-zepatier-elbasvir-and-grazoprevi
